Flow Neuroscience in a $9 million Series A led by Khosla Ventures, CSS group and Zühlke Ventures.

Flow Neuroscience, a Malmö, Sweden-based medical device company, announced the completion of a $9 million Series A funding round.

The money was raised from investors led by existinh American shareholders Khosla Ventures, CSS group through SwissHealth Ventures and Zühlke Ventures.

The round was also joined by Kirin Holdings through Kirin Health Innovation fund led by Global Brain, a top venture capital based in Japan, SOSV’s HAX, as well as the San Francisco based patent firm Schox.

Proceeds will be used to advance the company's existing depression treatment to be more patient-specific and will accelerate the development of non-pharmaceutical self-managed solutions for other mental health disorders, such as anxiety and drive US expansion through clinical trials and FDA approval.

Flow Neuroscience, founded in 2016 by CEO Daniel Månsson and Erik Rehn, developed a new kind of depression treatment which combines an easy-to-use brain stimulation headset with an engaging, personalized mobile app to target both the physical and behavioural elements of major depressive disorder (MDD).

The company previously raised almost $3 million, with the last round in 2019.